HIV Drug Lawsuit

If you have taken one of the following of Gilead’s tenofovir disoproxil fumarate (TDF) drugs listed below and then suffered from kidney disease and/or bone density loss — you may be entitled to compensation:

• Truvada
• Viread
• Atripla
• Complera
• Stribild

What Are The Kidney Injuries?

The kidney injuries related to Gilead’s HIV drugs include:

• Chronic kidney disease
• Acute kidney injury
• Acute renal failure
• Fanconi syndrome
• Tubular dysfunction

What Are The Bone Injuries?

The bone injuries related to Gilead’s HIV drugs include:

• Osteoporosis
• Osteopenia
• Bone fractures

The FDA approved Gilead’s TDF as an oral HIV medication in October 2001.

Gilead allegedly knew as far back as this that TDF could cause serious side effects because it had to be given in such high doses to be effective due to its low bio availability.

Excess TDF in the body is absorbed by the bones and kidneys.

They tested a new formula tenofovir alafenamide fumarate (TAF) in April 2001 which achieved the same therapeutic effect of their TDF drug but with safer results.

Gilead continued to market TDF, however, to maximize the profits of this drug and shelved TAF.

The company earned billions each year and it became one of the most prescribed HIV medications in the country.

The Los Angeles Times reported that by shelving the less toxic drug TAF, Gilead could then patent the drug separately and use it when the TDF patent ran out in 20 years.

In November 2015, the FDA approved Gilead’s TAF drug in a single-tablet combination pill called Genvoya.

TAF is also in the HIV single-tablet regimes Biktarvy and Descovy.

The company is now telling doctors to have patients switch to this HIV drug to reduce the risk of harm to their kidneys and bones.

If you, or a loved one, has taken one of the HIV drug containing TDF and subsequently suffered from kidney or bone injuries you may be able to file an HIV drug lawsuit.

Fill out the form on this page so we can discuss your legal options with one of our HIV lawyers.